TP53-positive clones are responsible for drug-tolerant persister and recurrence of HER2-positive breast cancer

MLA

Hideki Watanabe, et al. “TP53-Positive Clones Are Responsible for Drug-Tolerant Persister and Recurrence of HER2-Positive Breast Cancer.” Breast Cancer Research and Treatment, vol. 196, Sept. 2022, pp. 255–66. EBSCOhost, https://doi.org/10.1007/s10549-022-06731-z.

APA

Hideki Watanabe, Hiroshi Nakagomi, Yosuke Hirotsu, Kenji Amemiya, Hitoshi Mochizuki, Masayuki Inoue, Ayako Kimura, & Masao Omata. (2022). TP53-positive clones are responsible for drug-tolerant persister and recurrence of HER2-positive breast cancer. Breast Cancer Research and Treatment, 196, 255–266. https://doi.org/10.1007/s10549-022-06731-z

Chicago

Hideki Watanabe, Hiroshi Nakagomi, Yosuke Hirotsu, Kenji Amemiya, Hitoshi Mochizuki, Masayuki Inoue, Ayako Kimura, and Masao Omata. 2022. “TP53-Positive Clones Are Responsible for Drug-Tolerant Persister and Recurrence of HER2-Positive Breast Cancer.” Breast Cancer Research and Treatment 196 (September): 255–66. doi:10.1007/s10549-022-06731-z.